Xeris Pharmaceuticals Inc (NASDAQ:XERS) has earned an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and three have given a strong buy recommendation to the company.

Brokerages have set a twelve-month consensus price target of $26.50 for the company and are expecting that the company will post ($1.28) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Xeris Pharmaceuticals an industry rank of 107 out of 255 based on the ratings given to its competitors.

A number of research analysts have issued reports on the stock. Mizuho assumed coverage on shares of Xeris Pharmaceuticals in a research note on Monday, July 16th. They set a “buy” rating for the company. Jefferies Financial Group assumed coverage on shares of Xeris Pharmaceuticals in a research note on Monday, July 16th. They set a “buy” rating and a $23.00 target price for the company. Royal Bank of Canada assumed coverage on shares of Xeris Pharmaceuticals in a research note on Monday, July 16th. They set an “outperform” rating and a $24.00 target price for the company. Finally, Leerink Swann assumed coverage on shares of Xeris Pharmaceuticals in a research note on Monday, July 16th. They set an “outperform” rating and a $24.00 target price for the company.

Shares of NASDAQ:XERS traded up $0.89 during trading on Monday, reaching $27.00. 81,194 shares of the company’s stock traded hands, compared to its average volume of 61,715. Xeris Pharmaceuticals has a 12 month low of $15.75 and a 12 month high of $27.51.

Xeris Pharmaceuticals (NASDAQ:XERS) last announced its quarterly earnings data on Monday, August 13th. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($2.19). The company had revenue of $0.82 million for the quarter, compared to analyst estimates of $0.30 million. equities analysts expect that Xeris Pharmaceuticals will post -8.36 earnings per share for the current fiscal year.

In other news, major shareholder Palmetto Partners, Ltd. bought 150,000 shares of Xeris Pharmaceuticals stock in a transaction on Monday, June 25th. The stock was purchased at an average cost of $15.00 per share, with a total value of $2,250,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider James E. Flynn bought 750,000 shares of Xeris Pharmaceuticals stock in a transaction on Monday, June 25th. The shares were purchased at an average cost of $15.00 per share, with a total value of $11,250,000.00. The disclosure for this purchase can be found here.

A number of institutional investors have recently bought and sold shares of XERS. Redmile Group LLC acquired a new position in Xeris Pharmaceuticals during the 2nd quarter valued at about $45,792,000. OppenheimerFunds Inc. acquired a new stake in shares of Xeris Pharmaceuticals in the 2nd quarter worth approximately $18,980,000. FMR LLC acquired a new stake in shares of Xeris Pharmaceuticals in the 2nd quarter worth approximately $15,218,000. Federated Investors Inc. PA acquired a new stake in shares of Xeris Pharmaceuticals in the 2nd quarter worth approximately $5,694,000. Finally, Granahan Investment Management Inc. MA acquired a new stake in shares of Xeris Pharmaceuticals in the 2nd quarter worth approximately $2,481,000. 45.89% of the stock is owned by hedge funds and other institutional investors.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Featured Story: Trading Strategy

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.